Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study

医学 安慰剂 内科学 不利影响 临床终点 人口 2019年冠状病毒病(COVID-19) 临床试验 疾病 传染病(医学专业) 替代医学 环境卫生 病理
作者
Xiaohong Fan,Xiahong Dai,Yun Ling,Lihua Wu,Lingling Tang,Chunxian Peng,Chaolin Huang,Hongyan Liu,Hongzhou Lu,Xinghua Shen,Wei Zhang,Furong Wang,Guangming Li,Ming Li,Yanming Huang,Hongying Zhang,Minghui Li,Fei Ren,Yuanyuan Li,Chenfan Liu
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (2): 129-139 被引量:25
标识
DOI:10.1016/s1473-3099(23)00577-7
摘要

BackgroundSpread of SARS-CoV-2 led to a global pandemic, and there remains unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has potent activity against SARS-CoV-2, was compared with a placebo in this phase 3 study to investigate its efficacy and safety in patients with mild-to-moderate COVID-19.MethodsThis multicentre, double-blind, phase 3, randomised controlled study enrolled adults in hospitals for infectious diseases and tertiary general hospitals in China. Eligible patients were randomly assigned in a 1:1 ratio using permuted block randomisation to receive oral VV116 (0·6 g every 12 h on day 1 and 0·3 g every 12 h on days 2–5) or oral placebo (on the same schedule as VV116) for 5 days. Randomisation stratification factors included SARS-CoV-2 vaccination status and the presence of high-risk factors for progression to severe COVID-19. Inclusion criteria were a positive SARS-CoV-2 test, an initial onset of COVID-19 symptoms 3 days or less before the first study dose, and a score of 2 or more for any target COVID-19-related symptoms in the 24 h before the first dose. Patients who had severe or critical COVID-19 or who had taken any antiviral drugs were excluded from the study. The primary endpoint was the time to clinical symptom resolution for 2 consecutive days. Efficacy analyses were performed on a modified intention-to-treat population, comprising all patients who received at least one dose of VV116 or placebo, tested positive for SARS-CoV-2 nucleic acid, and did not test positive for influenza virus before the first dose. Safety analyses were done on all participants who received at least one dose of VV116 or placebo. This study was registered with ClinicalTrials.gov, NCT05582629, and has been completed.FindingsA total of 1369 patients were randomly assigned to treatment groups and 1347 received either VV116 (n=674) or placebo (n=673). At the interim analysis, VV116 was superior to placebo in reducing the time to sustained clinical symptom resolution among 1229 patients (hazard ratio [HR] 1·21, 95% CI 1·04–1·40; p=0·0023). At the final analysis, a substantial reduction in time to sustained clinical symptom resolution was observed for VV116 compared with placebo among 1296 patients (HR 1·17, 95% CI 1·04–1·33; p=0·0009), consistent with the interim analysis. The incidence of adverse events was similar between groups (242 [35·9%] of 674 patients vs 283 [42·1%] of 673 patients).InterpretationAmong patients with mild-to-moderate COVID-19, VV116 significantly reduced the time to sustained clinical symptom resolution compared with placebo, with no observed safety concerns.FundingShanghai Vinnerna Biosciences, Shanghai Science and Technology Commission, and the National Key Research and Development Program of China.TranslationFor the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
redking发布了新的文献求助10
刚刚
2秒前
3秒前
4秒前
4秒前
HuiJN完成签到 ,获得积分10
4秒前
锤子完成签到,获得积分10
5秒前
在水一方应助lizibelle采纳,获得10
6秒前
hoyden完成签到,获得积分10
6秒前
Stardust发布了新的文献求助10
7秒前
9秒前
momo发布了新的文献求助10
10秒前
10秒前
乐乐应助Mo采纳,获得10
11秒前
11秒前
Liufgui应助Z6kjoA采纳,获得20
11秒前
爆米花应助科研通管家采纳,获得10
13秒前
NexusExplorer应助科研通管家采纳,获得10
13秒前
cangy发布了新的文献求助10
13秒前
英姑应助科研通管家采纳,获得10
13秒前
地表飞猪应助科研通管家采纳,获得10
13秒前
桐桐应助科研通管家采纳,获得10
13秒前
14秒前
Akim应助科研通管家采纳,获得10
14秒前
Orange应助科研通管家采纳,获得10
14秒前
地表飞猪应助科研通管家采纳,获得10
14秒前
科研通AI2S应助科研通管家采纳,获得10
14秒前
酷波er应助科研通管家采纳,获得10
14秒前
地表飞猪应助科研通管家采纳,获得10
14秒前
14秒前
YamDaamCaa应助科研通管家采纳,获得30
14秒前
luo关闭了luo文献求助
15秒前
Jogging完成签到,获得积分10
16秒前
Villanellel发布了新的文献求助30
16秒前
李健应助ttt采纳,获得10
16秒前
科目三应助xueyu采纳,获得10
17秒前
Jello完成签到,获得积分10
20秒前
20秒前
111完成签到,获得积分10
21秒前
qq完成签到 ,获得积分10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173